- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: APN-311 | Ch14.18 | MAb-14.18 | Unituxin®
dinutuximab is an approved drug (FDA (2015))
Compound class: Antibody
Comment: Dinutuximab is a chimeric mouse/human monoclonal antibody targeting ganglioside-GD2.
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record.
A patent search identifies US20140170155  as the applicable patent. US20140170155 reveals APN311 as a formulation of the mouse-human chimeric anti-GD2 antibody ch14.18 recombinantly produced in Chinese hamster ovary (CHO) cells. Efficacy of the preferred antibody was determined by its cytolysis capacity in GD2-expressing cells, as determined by a complement dependent cytolysis assay.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖
|Approved drug?||Yes (FDA (2015))|
|International Nonproprietary Names|
|APN-311 | Ch14.18 | MAb-14.18 | Unituxin®|
|GtoPdb PubChem SID||249565662|
|Search PubMed clinical trials||dinutuximab|
|Search PubMed titles||dinutuximab|
|Search PubMed titles/abstracts||dinutuximab|